Global Navigation Element.
 


Spring 2014 Vol. 13 Number 2



Next
Table of Contents
Previous

Bookmark and Share


FROM THE EDITORS

Academies Welcome New IOM President

C.D. Mote Jr., Victor J. Dzau, and Ralph J. Cicerone photo by Cable Risdon

Victor J. Dzau, M.D., is an internationally recognized trailblazer in translational research, health innovation, and global health care strategy and delivery. On July 1, he takes on an entirely new role as he begins a six-year term as president of the Institute of Medicine.

Dzau takes the helm at IOM after serving nearly 10 years as chancellor for health affairs at Duke University and president and CEO for Duke University Health System. While at Duke, he was the guiding force in establishing several new initiatives, including the Duke Translational Medicine Institute, Duke Global Health Institute, Duke-NUS Medical School in Singapore, and the Duke Institute for Health Innovation. Before that, Dzau held influential posts with Harvard Medical School, Brigham and Women's Hospital, and Stanford University.

Dzau is also a highly regarded researcher. His work in the lab laid the foundation for the development of angiotensin-converting-enzyme (ACE) inhibitors, which are used globally for the treatment of high blood pressure and congestive heart failure. He pioneered gene therapy for vascular disease, being the first to introduce DNA decoy molecules to block transcriptions as gene therapy in humans. Dzau was elected to the IOM in 1998 and has served on several of its leadership committees.

"As a physician-scientist and leader in academic medicine," said outgoing IOM president Harvey V. Fineberg, "Victor has consistently demonstrated inspirational leadership, innovative thinking, and multifaceted achievement. Now, all of us at the IOM, both members and staff, will benefit more fully from his leadership." Fineberg, who served 12 years as IOM's president, is joining the faculty of the University of California, San Francisco, for a one-year appointment as a presidential chair and will focus on global health policy and analysis.

"I am humbled and honored to be selected to lead the IOM at a time of unprecedented opportunities and challenges in health, health care, and biomedical sciences," Dzau said. "Harvey Fineberg has been an exceptional leader of the IOM, and I am committed to building on his outstanding work and advancing the impact of the IOM on the nation and globally."



Previous Table of Contents Next


Copyright 2014 National Academy of Sciences